Anti-tumor necrosis factor therapy in intestinal Behçet’s disease

Jihye Park, Jae Hee Cheon

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)


Intestinal Behçet’s disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet’s disease is difficult to treat and often requires surgery because of the failure of conventional medical treatment. Administration of anti-tumor necrosis factor–α, a potential therapeutic strategy, is currently under active clinical investigation, and evidence of its effectiveness for both intestinal Behçet’s disease and inflammatory bowel diseases has been accumulating. Here, we review updated data on current experiences and outcomes after the administration of anti-tumor necrosis factor–α for the treatment of intestinal Behçet’s disease. In addition to infliximab and adalimumab, which are the most commonly used agents, we describe agents such as golimumab, etanercept, and certolizumab pegol, which have recently been shown to be effective in refractory intestinal Behçet’s disease. This review also discusses safety issues associated with anti-tumor necrosis factor–α, including vulnerability to infections and malignancy.

Original languageEnglish
Pages (from-to)623-632
Number of pages10
JournalGut and liver
Issue number6
Publication statusPublished - 2018 Nov

Bibliographical note

Publisher Copyright:
© 2018 Editorial Office of Gut and Liver. All Rights Reserved.

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Anti-tumor necrosis factor therapy in intestinal Behçet’s disease'. Together they form a unique fingerprint.

Cite this